OncoBEAM™ for Colorectal Cancer

Highly sensitive analysis for improved patient stratification

Liquid biopsy delivers rapid results and systemic analysis

OncoBEAM™ for metastatic colorectal cancer (mCRC) delivers rapid results to drive treatment decisions with real-time information about clinically actionable mutations in genes such as RAS and BRAF. The National Comprehensive Cancer Network (NCCN), American Society of Clinical Oncology (ASCO) and European Society for Medical Oncology (ESMO) guidelines1-3 all recommend RAS and BRAF mutation testing before prescribing anti-EGFR therapy.

Thanks to our highly-sensitive BEAMing technology, a liquid biopsy with OncoBEAM™ requires only a simple blood draw to provide a current view of a tumor’s mutation status in 5 to 7 days.

Get results in 5–7 days

Patient visits clinic for blood draw

Patient visits clinic for blood draw

Sample is tested with OncoBEAM™

Sample is tested with OncoBEAM™

Results are reported within 5-7 days

Results are reported within 5-7 days

OncoBEAM™ assays for colorectal cancer provide results in just 5 to 7 days from our CLIA-certified laboratory, helping doctors to make faster treatment decisions for patients.

Address treatment resistance earlier

Emergence of resistance mutations is common in metastatic colorectal cancer (mCRC) patients treated with anti-EGFR therapy.4,5 The OncoBEAM™ test has been shown to reveal these resistance mutations sooner than imaging6,7 providing early insight to plan for next steps.

Our Test Menu

OncoBEAM™ CRC1: KRAS, NRAS, BRAF

KRAS/NRAS: Codons 12, 13, 59, 61, 117, and 146
BRAF: V600E

A comprehensive RAS panel for 33 mutations

KRAS mutations in Codons 12 and 13 are no longer the sole mutations that guide therapy decisions. Patients with mCRC tumors exhibiting a new RAS mutation are unlikely to significantly benefit from anti-EGFR therapy.8

The extensive OncoBEAM™ RAS panel provides oncologists with an accurate assessment of RAS mutation status to assist in identifying appropriate therapy options for mCRC patients.

Additional RAS mutations in codons other than 12 and 13 in KRAS and also including NRAS were revealed in approximately 15% of patients originally classified as wild type through tissue testing8

BRAF tumor mutation can indicate poor prognosis

BRAF mutations are associated with resistance to anti-EGFR therapy. Patients whose tumor harbors a BRAF mutation generally have poor outcomes and have not been shown to benefit from anti-EGFR therapy.9  However, new data from recent clinical trials combining BRAF inhibitors with anti-EGFR therapy show have shown promising results.6,7

The OncoBEAM™ CRC1 mutation test includes BRAF to provide a comprehensive analysis of clinically actionable mutations as recommended by clinical practice guidelines.3

Case scenario

Avoiding multiple invasive biopsies

A 65 year old man presents with metastatic colorectal cancer upon routine screening. Imaging reveals liver lesions that are unresectable due to size and insufficient future liver remnant. Systemic therapy is recommended to attempt conversion to resectable hepatic disease. In accordance with clinical practice guidelines, tumor RAS/BRAF status must first be evaluated.

OncoBEAM™ CRC1 testing is ordered to evaluate the mutational status of both primary and metastatic sites. Testing reveals a RAS mutant tumor, eliminating consideration of anti-EGFR therapy.

The OncoBEAM™ solution

OncoBEAM™ CRC1 test enabled a systemic mutation assessment of the patient’s tumor mutation status without the need for multiple invasive biopsies at each site.

FAQs

What is BEAMing technology?

BEAMing is a highly sensitive quantitative PCR technology that employs bead-based amplification in water-in-oil emulsions and allele-specific hybridization followed by flow cytometry for detecting small amounts of mutated DNA released by tumors into the blood circulation. Our BEAMing assays are designed to detect specific clinically relevant hotspot mutations and can be used to calculate the fraction of circulating DNA that contains a specific mutation at the time a sample is drawn.

What are the advantages of BEAMing technology?

The advantages of BEAMing technology include:

  • Minimally invasive
  • Provides real-time information about the current mutational status of the primary tumor and metastatic sites
  • Eliminates selection bias inherent with tissue samples
  • Reveals mutational status of a tumor when tissue is unavailable or inaccessible
  • Highly sensitive detection of mutant DNA with detection of mutant tumor DNA in a background of wild-type DNA at ratios as low as 2 in 10,000 (analytical sensitivity of 0.02%)
  • Enables monitoring of drug response and disease recurrence
Can BEAMing technology be used for diagnosing cancer?

No, BEAMing today is used for mutation testing in advanced and metastatic cancer patients.

How are OncoBEAM™ tests billed and reimbursed?

Sysmex Inostics accepts all insurance plans, but OncoBEAM™ tests are currently not in-network with most carriers. We are working to become in-network with payors. Sysmex Inostics directly bills insurance or Medicare and patients are not responsible for any balance that is not covered by insurance or Medicare. Deductibles may apply if applicable. Sysmex Inostics does not accept uninsured patients at this time.

Get a real-time snapshot of your patient's tumor

Download a test requisition form

Complete and send to our lab with your patient’s blood sample for testing

Access the Provider Portal

Log in to view test results and the latest clinical content from OncoBEAM™

Request more information

Get answers to your questions about OncoBEAM™

References:

  1. Van Cutsem, E. et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann. Oncol. 27, 1386–1422 (2016).
  2. Sepulveda, A. R. et al. Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology. J. Clin. Oncol. 35, 1453–1486 (2017).
  3. NCCN guidelines colon cancer 2.2017
  4. Diaz, L. A. et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 486, 537–540 (2012).
  5. Morelli, M. P. et al. Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment. Ann. Oncol. 26, 731–736 (2015).
  6. Yaeger, R. et al. Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients. Clin. Cancer Res. 21, 1313–1320 (2015).
  7. Tabernero, J. et al. Phase 2 results: Encorafenib (ENCO) and cetuximab (CETUX) with or without alpelisib (ALP) in patients with advanced BRAF-mutant colorectal cancer (BRAFm CRC). ASCO Meeting Abstracts 34, 3544 (2016).
  8. Sorich, M. J. et al. Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials. Ann. Oncol. 26, 13–21 (2015).
  9. Pietrantonio, F. et al. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: A meta-analysis. Eur. J. Cancer 51, 587–594 (2015).